Form 4: Pacira BioSciences Chief Medical Officer Reports Stock Transactions

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, reports acquiring shares through an employee stock purchase plan, shares withheld for tax obligations, and sales under a pre-arranged 10b5-1 trading plan.

Summary

• On June 28, 2024, Jonathan Slonin acquired 437.271 shares of Pacira BioSciences common stock at $24.319 per share through the employee stock purchase plan.
• On July 1, 2024, 914 shares were withheld by Pacira BioSciences at $28.46 per share to cover tax obligations related to the vesting of a restricted stock unit award.
• On July 2, 2024, Slonin sold 2,836 shares at $28.25 per share under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Slonin beneficially owns 95,556.746 shares of Pacira BioSciences common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and explained, with no clear indication of strong positive or negative sentiment from the executive.

Positives

• The acquisition of shares through the employee stock purchase plan demonstrates the executive's investment in the company's future.

Negatives

• The sale of shares, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• Continued sales under the 10b5-1 trading plan could put downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the executive's trading activity provides insight into their current view of the company's value.

Industry Context

Executive stock transactions are common and closely watched in the pharmaceutical industry, as they can signal confidence or concern about a company's prospects. Rule 10b5-1 plans are frequently used to avoid insider trading accusations.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include stock options and restricted stock units, similar to the award mentioned in this filing.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock holdings while avoiding insider trading concerns.
• Comparing Slonin's trading activity to that of executives at similar-sized biotech companies (e.g., companies with market caps between $1 billion and $5 billion) could provide additional context.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how they are interpreted.

Key Dates